BMS

CheckMate 153

NCT02066636

JCP005

A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen (CheckMate153)

Status:

Closed to Accrual

26459-200.png

III

Phase

Line of Therapy.png

1st

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

EGFR

Investigational

Product

Nivolumab

Anti-PD-1 Monoclonal Antibody (i.v.)

Treatment Arms

o Experimental with 2 cohorts